Clin Gastroenterol Hepatol
High rate of CYP2C19 rapid metabolism found in GERD patients
A single-center retrospective study of 421 GERD patients revealed that 44% were rapid or ultrarapid CYP2C19 metabolizers. Barrett’s esophagus and erosive esophagitis were more frequently observed in ultrarapid metabolizers compared with those with normal metabolism. Adjusting PPI therapy based on CYP2C19 genotype showed a trend toward improved symptom resolution.
Clinical takeaway: Consider CYP2C19 genotyping in patients with persistent GERD symptoms despite optimized PPI therapy to guide dosing or alternative treatment strategies.
Source:
Creech L, et al. (2025, November 3). Clin Gastroenterol Hepatol. High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism among Patients with Gastroesophageal Reflux Disease. https://pubmed.ncbi.nlm.nih.gov/41197932/